Examining the impact of TGF-ß activity on fibroblast infiltration and immune exclusion in MIBC.
Abstract
851 Background: In urothelial cancer, transforming growth factor β (TGF-β) signaling in fibroblasts has been correlated with poor respose to immunotherapy (IO). We examined TGF- β activity scores in relation to the tumor micro-environment (TME) from muscle invasive bladder cancer (MIBC) patients and whether this correlated to response to neoadjuvant chemoIO utilized in the BLASST-01 trial. Methods: We assessed a prospective commercial cohort (PCC) consisting of the de-identified and anonymized transcriptome-wide expression profiles of N = 604 MIBC patients from the clinical use of the Decipher Bladder TURBT test that were available in the Decipher GRID registry (NCT02609269). Molecular subtypes were categorized by the consensus-MIBC subtyping model. Using GRID signatures, we applied the molecular signatures database hallmark gene set collection to quantify TGF-β hallmark signaling scores. Furthermore, we used TIDE (a computational framework on Tumor Immune Dysfunction and Exclusion) to quantify TME-related scores for cancer associated fibroblasts (CAF), immune exclusion, T regulatory cells and cytotoxic T-lymphocytes. The BLASST-01 trial investigated 4 cycles of neoadjuvant gemciatine, cisplatin, and nivoumab followed by radical cystectomy (RC). Pre-treament tumor specimens were examined for associations between molecular scores and pathological response (≤ypT1N0) at RC. Multivariable logistic regression analyses for pathologic response were adjusted for patient age and sex. Results: Intersection of TGF-β hallmark signaling scores with consensus molecular subtypes in the PCC cohort, we found elevated scores for the stroma-rich molecular subtype (p < 0.001). Furthermore, we found TGF-β scores had a significant positive correlation with CAFs (r = 0.41, p < 0.001), T regulatory cells (r = 0.33, p < 0.001) and immune exclusion (r = 0.47, p < 0.001), whereas we found a significant negative correlation between TGF-β hallmark signaling scores and infiltration of cytotoxic T-lymphocytes (r = -0.31, p < 0.001) and interferon γ (r = -0.35, p < 0.001). Additionally, TGF-β was highly correlated to hallmarks pathways related to epithelial-mesenchymal transition (EMT) (r = 0.36, p < 0.001) and angiogenesis (r > 0.31, p < 0.001) For BLASST-01, transcriptome data were available for 37/43 (86%); median age was 65 (IQR, 58-70), 41% were female, 89% were cT2N0 and 35% had pathological complete response. Higher scores for TGF-β signaling (OR 0.03, p < 0.005), immune exclusion (OR 0.37, p < 0.03) and CAFs (OR 0.41, p < 0.03) were associated with no pathological response, whereas cytotoxic T lymphocytes were significantly associated with pathological complete response (OR 7.04, p < 0.02). Conclusions: The present study demonstrates that molecular TGF-β activity scores are associated with fibroblast infiltration and immune exclusion, suggesting TGF-β attenuates response to neoadjuvant IO for MIBC.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (15)
Shilpa Gupta
Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA
Joep Jacobus de Jong
Erasmus MC Cancer Institute, Rotterdam, Netherlands
Mohammed Alshalalfa
Jonathan Chou
Helen Diller Family Comprehensive Cancer Center, University of California
Vadim S. Koshkin
Division of Hematology/Oncology, Department of Medicine University of California‐San Francisco San Francisco California USA
Terence W. Friedlander
David Yoonsuk Oh
University of California, San Francisco, San Francisco, CA
Sima P. Porten
Carissa E Chu
University of California San Francisco, San Francisco, CA
Nataliya Mar
University of California Irvine, Irvine, CA
Alexander Sasse
Anthony C. Wong
Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA
James A. Proudfoot
Veracyte Inc, San Francisco, CA
Elai Davicioni
Steven Neema Seyedin
University of California San Francisco, San Francisco, CA